Evidence map›Paper›PMID 40834860›Full record

ArticleCell reports. Medicine2025

TYK2 inhibition enhances Treg differentiation and function while preventing Th1 and Th17 differentiation.

Karoliina Tuomela, Rosa V Garcia, Dominic A Boardman, Pedram Tavakoli, Maria Ancheta-Schmit, Ho Pan Sham, Lihong Cheng, Mary Struthers, Brian Bressler, Bruce A Vallance and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Karoliina TuomelaDepartment of Surgery, University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Rosa V GarciaDepartment of Surgery, University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Dominic A BoardmanDepartment of Surgery, University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Pedram TavakoliDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Maria Ancheta-SchmitDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Ho Pan ShamBC Children's Hospital Research Institute, Vancouver, BC, Canada; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Lihong ChengDiscovery Immunology, Bristol-Myers Squibb, Princeton, NJ, USA.
Mary StruthersDiscovery Immunology, Bristol-Myers Squibb, Princeton, NJ, USA.
Brian BresslerDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Bruce A VallanceBC Children's Hospital Research Institute, Vancouver, BC, Canada; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Qihong ZhaoDiscovery Immunology, Bristol-Myers Squibb, Princeton, NJ, USA.
Megan K LevingsDepartment of Surgery, University of British Columbia, Vancouver, BC, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada; School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada. Electronic address: mlevings@bcchr.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Janus kinase (JAK) inhibitors are widely used to inhibit inflammatory cytokine signaling in autoimmune and inflammatory diseases, but their effect on regulatory T cells (Tregs) is poorly characterized. We investigated the effect of a JAK inhibitor, upadacitinib, on human Treg differentiation and phenotype in comparison to BMS-986202, a selective Tyrosine kinase 2 (TYK2) inhibitor. Both upadacitinib and BMS-986202 blocked naive CD4

Indexed as

Cell DifferentiationProtein Kinase InhibitorsTh17 CellsTh1 CellsT-Lymphocytes, RegulatoryTYK2 KinaseHeterocyclic Compounds, 3-RingHumansInflammatory Bowel DiseasesInterleukin-2Signal TransductionHeterocyclic Compounds, 3-RingInterleukin-2Protein Kinase InhibitorsTYK2 KinaseTYK2 protein, humanupadacitinibautoimmunityimmune toleranceinflammatory bowel diseaseJAK inhibitionregulatory T cellTh17 differentiationTh1 differentiationTreg differentiationTYK2 inhibition

Identifiers

PMID40834860
PMCPMC12490244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.